TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
- Written by PR Newswire
- Hansoh plans to develop 'TU2670 (Hansoh's code: HS-10518)' as a best-in-class novel GnRH antagonist in China- TiumBio will complete the last patient dosing in a Phase 2a clinical trial of TU2670 in endometriosis in Europe by the end of the year
BOSTON and SEONGNAM, South Korea, July 5, 2023 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ:...
